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Predicting Long-Term Outcomes in Asymptomatic or
Minimally Symptomatic Patients With HCM
Back to Basics*Harry Rakowski, MD, Qin Li, MDToronto, Ontario, CanadaHypertrophic cardiomyopathy (HCM) is a hetero-
geneous inherited cardiac condition that affects
0.2% of the general population (1). It is typiﬁed
by a hypertrophied nondilated left ventricle (LV)
with resting or provocable LV outﬂow tract (OT)
obstruction, observed in up to two-thirds of patients
(2). Signiﬁcant efforts have been made in the past 2
decades to identify predictors of adverse clinical
outcomes such as sudden cardiac death, heart failure,
and stroke. These have included advanced imaging
to quantitate the location and degree of hypertrophy
and myocardial ﬁbrosis, genetic testing, detection of
ventricular and atrial arrhythmias, and assessment of
blood pressure response to exercise. Despite the
value of conventional risk stratiﬁcation, we continue
to be humbled by patients who appear to have a low-
risk proﬁle and few cardiac symptoms yet present
with devastating outcomes.See page 26Exercise Intolerance in HCM
Although many patients with HCM have minimal
symptoms with near-normal life expectancy, many
experience exercise limitations due to dyspnea,
chest pain, pre-syncope or syncope, which may be
debilitating. Symptoms may be due to myocardial
ischemia, diastolic or systolic dysfunction, LVOT
obstruction, atrial ﬁbrillation (AF), or mitral re-
gurgitation. Histologically, HCM is characterized*Editorials published in JACC: Cardiovascular Imaging reﬂect the views of
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contents of this paper to disclose.by myocyte hypertrophy and disarray, interstitial
ﬁbrosis, as well as small vessel narrowing along with
reduced capillary density (3). Such changes, coupled
with increased myocardial oxygen demand due to LV
hypertrophy, can result in a supply–demandmismatch,
compromising endocardial blood ﬂow and leading to
ischemic symptoms. This is supported by studies in
myocardial perfusion using 201Tl scintigraphy, posi-
tron emission tomography using dipyridamole, and
cardiac magnetic resonance stress testing.
Diastolic dysfunction is a well-recognized cause of
symptoms in HCM patients, regardless of the
presence of obstruction, and likely reﬂects increased
myocardial stiffness. Echocardiographic Doppler
indices and myocardial mechanics are often
abnormal, including increased E/E0 ratio, elevated
left atrial volume, as well as prolonged time for LV
untwisting and lower apical reverse rotation fraction
on diastolic strain analysis (4). Markers of diastolic
dysfunction correlated with lower peak VO2 on ex-
ercise testing and worse New York Heart Associa-
tion functional class (4,5). Increased heart rate in
response to exercise can further shorten diastole,
impairing LV ﬁlling. Resting LVOT obstruction
occurs in 25% to 30% of patients, and up to two-
thirds of all HCM patients have signiﬁcant LVOT
obstruction after provocation with Valsalva and/or
exercise. However, some patients with very high
LVOT gradients may be relatively asymptomatic,
whereas others with lower gradients can be quite
symptomatic. Thus, there is a complex interplay of
factors causing symptoms in HCM patients.
Current Evidence for Using Stress Echocardiography
in HCM Patients
The number of metabolic equivalents (METs)
achieved and abnormal heart rate recovery (HRR)
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studies in non-HCM patients (6–8). In patients
with HCM, exercise testing is useful for provoking
latent obstruction by reduction of preload in the
upright position and augmentation of LV contrac-
tility, detecting abnormal blood pressure response
during exercise and exercise-induced ventricular
arrhythmias (2). Thus, stress testing is a Class IIa
indication for the quantiﬁcation of provocable
LVOT gradient, risk stratiﬁcation of sudden cardiac
death, and assessment of functional capacity and
response to therapy (2).
Exercise Capacity and Outcome in HCM Patients
In this issue of iJACC, Desai et al. (9) report that in
asymptomatic or minimally symptomatic HCM pa-
tients, the percent of predicted METs, abnormal
HRR, and AF independently predicted adverse
clinical outcomes. They studied a total of 426 pa-
tients over a 10-year period in a large HCM referral
center, with a mean follow-up period of 8.7  3.0
years. Patients with reduced ejection fraction<50%,
valvular heart disease, those undergoing invasive
therapies, and those with HCM of the elderly were
excluded. Overall, there were 116 (27%) non-
obstructive patients, 280 (66%) obstructive patients,
and 30 (7%) patients with apical HCM. There were
only 52 outcome events, which represents a linear rate
of <1.5%/year, conﬁrming that this was a relatively
healthy cohort. There were no signiﬁcant endpoint
differences due to LVOT obstruction, but only rela-
tively healthy patients were studied and the event rate
was low. Thus, despite a good sample size, the study
may be underpowered to draw this conclusion. How-
ever, importantly, there was a signiﬁcant difference in
combined outcome (death, appropriate implantable
cardioverter-deﬁbrillator discharges, congestive heart
failure requiring hospital stay) between groups of pa-
tientswho, on exercise testing, achieved different levels
ofMETs (>100%: n¼ 76 [18%]; 85%–100%: n¼ 82
[19%]; and <85%: n ¼ 268 [63%]). Despite being
asymptomatic or minimally symptomatic, 82% of pa-
tients failed to achieve age-sex predicted METs, sug-
gesting that over time, many patients accepted a lower
functional status without fully appreciating their lim-
itations. The event rateswere 1% for patients achieving
>100% predicted METs and remarkably 12% for
those achieving <85% of predicted METs. In addi-
tion, abnormal HRR and AF were also independent
predictors of adverse clinical outcome (p < 0.001).
Potentially important information such as scar burden
quantiﬁed by cardiac magnetic resonance and more
sophisticated measures of diastolic function were notavailable, which is an important study limitation. The
ﬁndings by Desai et al. (9) are in agreement with
previous stress echocardiographic studies. Sorajia et al.
(10) demonstrated that in minimally symptomatic
patients with obstructive HCM, a <60% predicted
peak myocardial O2 consumption was associated with
only a 59% 4-year survival free of death and severe
symptoms. Peteiro et al. (11) demonstrated that
neither resting nor exercise-induced LVOT gradients
correlated with the combined endpoints of cardiac
death, transplantation, appropriate implantable
cardioverter-deﬁbrillator discharge, stroke, myocar-
dial infarction, or heart failure. Interestingly, exercise-
induced wall motion abnormalities and METs
achieved were predictive of adverse outcomes, sug-
gesting that myocardial ischemia may be an important
factor in determining functional capacity and clinical
outcome. In the current study (9), AF was also a
predictor of adverse clinical outcome, underscoring
the importance of educating patients about recog-
nizing AF and treating it with anticoagulation to
prevent embolic stroke. There may also be intrinsic
abnormalities in the way patients with HCM respond
to exercise, as evidenced by the abnormal vagal reac-
tivation and abnormal HRR.Conclusions
The cause of reduced exercise capacity in HCM
patients is multifactorial and likely involves the
interplay of myocyte hypertrophy and disarray,
interstitial ﬁbrosis, microvascular ischemia, diastolic
dysfunction, and reduced systolic reserve. As we
continue to search for therapies that may delay or
arrest the development of hypertrophy and ﬁbrosis,
it is important to identify patients at higher risk of
devastating adverse clinical outcomes. Exercise
testing is a safe and effective way to assess patients’
true functional status and provides incremental in-
formation about long-term prognosis even when
patients are minimally symptomatic. As we evaluate
more complex testing to determine prognosis in
HCM, simple stress testing remains a very impor-
tant predictor of both functional capacity and
outcome. The study by Desai et al. (9) reminds us of
the value of going back to the basics in the risk
stratiﬁcation of patients with HCM.
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